In silico Molecular Docking and Design of Anti-Hepatitis B Drugs

Arooj, Mahira

doi:10.9790/3008-0364155

Cited by 2 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some in silico studies 53 have been used to identify drugs and predict their effectiveness in HBV treatment models in the chronic phase utilizing bioinformatics techniques. The study done by Arooj et al 53 compared the efficacy of lamivudine and adefonir among standard drugs and found out that lamivudine had a better efficacy that adefonir. This outcome is similar and comparable to the predictions of our mathematical model which revealed that lamivudine had a better efficacy than interferon alpha.…”

Section: Discussion Of Results and Conclusionmentioning

confidence: 99%

A theoretical model of chronic hepatitis B virus with suboptimal adherence and drug resistance

Manda

Chirove

2020

Math Methods in App Sciences

View full text Add to dashboard Cite

In this paper, we formulate and analyze a within-host hepatitis B viral theoretical mathematical model for hepatitis B virus infection in the chronic phase of liver cancer with suboptimal adherence and drug resistance. The model incorporates hepatocytes, hepatitis B virus, immune cells, and cytokine dynamics using a system of ordinary differential equations. Treatment was captured using efficacy functions replicating the realistic pharmacokinetics properties of two drugs, one of which is administered intravenously and the other orally. Our results suggest that natural drug resistance increases the hepatitis B virus burden more than suboptimal adherence to drugs from both monotherapies and combined therapies. The results also suggest that the inclusion of both immune cells and cytokine responses is essential and that combination therapies are more significant in reducing hepatitis B virus infection than monotherapies.

show abstract

Section: Discussion Of Results and Conclusionmentioning

confidence: 99%